Aspen Pharmacare results lift EBITDA and NHEPS on efficiency, APAC divestment
Aspen Pharmacare reported strong EBITDA and NHEPS growth with flat revenue, citing Commercial Pharma and efficiency gains. APAC divestment unlocked value, strengthened the balance sheet, and GLP-1s plus Sterile FDF are set to drive future growth.
Delivered strong EBITDA and NHEPS growth despite flat revenue, driven by Commercial Pharma and efficiency gains.
APAC divestment unlocked value and strengthened the balance sheet, while GLP-1s and Sterile FDF are set to drive future growth.Original document: Aspen Pharmacare Holdings Limited [APN…